Collaborations, Licensing and Other Arrangements (Tables)

12 Months Ended

Dec. 31, 2025

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Schedule of Total Revenue from Collaboration and Services

Revenue from collaborations and services were as follows (in thousands):

	Year Ended December 31,
	2025		2024		2023
UT CSA(1)	$	102,385	$	96,228	$	52,025
Amphastar co-promotion agreement		2,000		500		—
Cipla License and Distribution Agreement		1,222		1,247		147
Other		106		—		—
UT License Agreement		1,000		2,865		782
Total revenue from collaborations and services	$	106,713	$	100,840	$	52,954

_________________________

(1)Amounts consist of revenue recognized for Manufacturing Services to UT for the periods presented.

Schedule of Deferred Revenue Related to Revenue Recognized for Collaborations and Services

The activities and ending deferred balance for collaborations and services revenue is as follows (in thousands):

	December 31, 2025			December 31, 2024
Deferred revenue:
Beginning balance	$	63,567		$	78,879
Additions		93,454			85,528
Upfront and milestone payments		5,000			—
Collaborations and services revenue		(106,713	)		(100,840	)
Ending balance	$	55,308		$	63,567

United Therapeutics Corporation

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Schedule of Total Revenue from Collaboration and Services

Total revenue from UT was as follows (in thousands):

	Year Ended December 31,
	2025		2024		2023
Revenue from UT
Royalties(1)	$	128,116	$	102,335	$	71,979
UT CSA		102,385		96,228		52,025
UT License Agreement		1,000		2,865		782
Total revenue from UT	$	231,501	$	201,428	$	124,786

_________________________

Amounts consist of royalties associated with the UT License Agreement. The contract asset related to the royalties receivable of $30.2 million, $24.3 million and $21.7 million as of December 31, 2025, 2024 and 2023, respectively, was included in prepaid expense and other current assets in the consolidated balance sheets and collected in the following quarter

UT CSA

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Schedule of Total Revenue from Collaboration and Services

The portion of revenue related to each deliverable included in UT CSA revenue (in thousands) is as follows:

	Year Ended December 31,
	2025		2024		2023
UT CSA Revenue
Sale of product(1)		88,581		77,006		49,289
Recognition of previously deferred revenue		12,201		12,170		2,736
Other agreements		1,603		7,052		—
Total UT CSA revenue	$	102,385	$	96,228	$	52,025

Sale of product included revenue related to fully reimbursable costs associated with product sales and other miscellaneous charges of $0.9 million and $9.4 million for the years ended December 31, 2025 and 2024, respectively.